ProPhase Labs Stock (NASDAQ: PRPH) stock price, news, charts, stock research, profile.
Open | $6.320 |
Close | $5.440 |
Volume / Avg. | 1.177M / 30.362K |
Day Range | 5.330 - 6.320 |
52 Wk Range | 4.050 - 9.941 |
Market Cap | $108.271M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 43 |
Short Interest | 1.83% |
Days to Cover | 6.62 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of ProPhase Labs (NASDAQ: PRPH) through any online brokerage.
Other companies in ProPhase Labs’s space includes: Zevra Therapeutics (NASDAQ:ZVRA), Rani Therapeutics Hldgs (NASDAQ:RANI), Marinus Pharma (NASDAQ:MRNS), Alimera Sciences (NASDAQ:ALIM) and Anebulo Pharmaceuticals (NASDAQ:ANEB).
The latest price target for ProPhase Labs (NASDAQ: PRPH) was reported by HC Wainwright & Co. on Wednesday, February 21, 2024. The analyst firm set a price target for 11.00 expecting PRPH to rise to within 12 months (a possible 83.33% upside). 5 analyst firms have reported ratings in the last year.
The stock price for ProPhase Labs (NASDAQ: PRPH) is $6 last updated April 18, 2024 at 8:48 AM EDT.
A quarterly cash dividend of $0.30 per share of Class A Common Stock. The quarterly cash dividend was payable on June 3, 2022 to stockholders of record on May 24, 2022.
ProPhase Labs’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for ProPhase Labs.
ProPhase Labs is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.